Literature DB >> 9256481

Antibodies to several conformation-dependent epitopes of gp120/gp41 inhibit CCR-5-dependent cell-to-cell fusion mediated by the native envelope glycoprotein of a primary macrophage-tropic HIV-1 isolate.

F C Verrier1, P Charneau, R Altmeyer, S Laurent, A M Borman, M Girard.   

Abstract

The beta-chemokine receptor CCR-5 is essential for the efficient entry of primary macrophage-tropic HIV-1 isolates into CD4(+) target cells. To study CCR-5-dependent cell-to-cell fusion, we have developed an assay system based on the infection of CD4(+) CCR-5(+) HeLa cells with a Semliki Forest virus recombinant expressing the gp120/gp41 envelope (Env) from a primary clade B HIV-1 isolate (BX08), or from a laboratory T cell line-adapted strain (LAI). In this system, gp120/gp41 of the "nonsyncytium-inducing," primary, macrophage-tropic HIV-1BX08 isolate, was at least as fusogenic as that of the "syncytium-inducing" HIV-1LAI strain. BX08 Env-mediated fusion was inhibited by the beta-chemokines RANTES (regulated upon activation, normal T cell expressed and secreted) and macrophage inflammatory proteins 1beta (MIP-1beta) and by antibodies to CD4, whereas LAI Env-mediated fusion was insensitive to these beta-chemokines. In contrast soluble CD4 significantly reduced LAI, but not BX08 Env-mediated fusion, suggesting that the primary isolate Env glycoprotein has a reduced affinity for CD4. The domains in gp120/gp41 involved in the interaction with the CD4 and CCR-5 molecules were probed using monoclonal antibodies. For the antibodies tested here, the greatest inhibition of fusion was observed with those directed to conformation-dependent, rather than linear epitopes. Efficient inhibition of fusion was not restricted to epitopes in any one domain of gp120/gp41. The assay was sufficiently sensitive to distinguish between antibody- and beta-chemokine-mediated fusion inhibition using serum samples from patient BX08, suggesting that the system may be useful for screening human sera for the presence of biologically significant antibodies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9256481      PMCID: PMC23181          DOI: 10.1073/pnas.94.17.9326

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals.

Authors:  D R Burton; C F Barbas; M A Persson; S Koenig; R M Chanock; R A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

2.  Restriction of serum antibody reactivity to the V3 neutralizing domain of HIV gp120 with progression to AIDS.

Authors:  M Page; C Vella; T Corcoran; P Dilger; C Ling; A Heath; R Thorpe
Journal:  AIDS       Date:  1992-05       Impact factor: 4.177

3.  Semliki Forest virus expression system: production of conditionally infectious recombinant particles.

Authors:  P Berglund; M Sjöberg; H Garoff; G J Atkins; B J Sheahan; P Liljeström
Journal:  Biotechnology (N Y)       Date:  1993-08

4.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.

Authors:  T Muster; F Steindl; M Purtscher; A Trkola; A Klima; G Himmler; F Rüker; H Katinger
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

5.  Loss of serum antibodies to a conformational epitope of HIV-1/gp120 identified by a human monoclonal antibody is associated with disease progression.

Authors:  L A Cavacini; C L Emes; J Power; J Underdahl; R Goldstein; K Mayer; M R Posner
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-10

6.  Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody.

Authors:  M K Gorny; A J Conley; S Karwowska; A Buchbinder; J Y Xu; E A Emini; S Koenig; S Zolla-Pazner
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

7.  Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120.

Authors:  M R Posner; L A Cavacini; C L Emes; J Power; R Byrn
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-01

8.  Expression of HIV-1 envelope glycoproteins by Semliki Forest virus vectors.

Authors:  N L Paul; M Marsh; J A McKeating; T F Schulz; P Liljeström; H Garoff; R A Weiss
Journal:  AIDS Res Hum Retroviruses       Date:  1993-10       Impact factor: 2.205

9.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

Authors:  P Roben; J P Moore; M Thali; J Sodroski; C F Barbas; D R Burton
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

10.  Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding.

Authors:  Q J Sattentau; J P Moore
Journal:  J Exp Med       Date:  1991-08-01       Impact factor: 14.307

View more
  10 in total

1.  Properties of the naturally occurring soluble surface glycoprotein of ecotropic murine leukemia virus: binding specificity and possible conformational change after binding to receptor.

Authors:  H Ikeda; K Kato; T Suzuki; H Kitani; Y Matsubara; S Takase-Yoden; R Watanabe; M Kitagawa; S Aizawa
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  CCR5 coreceptor utilization involves a highly conserved arginine residue of HIV type 1 gp120.

Authors:  W K Wang; T Dudek; Y J Zhao; H G Brumblay; M Essex; T H Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

3.  New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection.

Authors:  Javier Garcia-Perez; Patricia Rueda; Isabelle Staropoli; Esther Kellenberger; Jose Alcami; Fernando Arenzana-Seisdedos; Bernard Lagane
Journal:  J Biol Chem       Date:  2010-11-30       Impact factor: 5.157

4.  Reduction of HIV-1 infectivity through endoplasmic reticulum-associated degradation-mediated Env depletion.

Authors:  Antonio Casini; Michele Olivieri; Lara Vecchi; Oscar R Burrone; Anna Cereseto
Journal:  J Virol       Date:  2014-12-24       Impact factor: 5.103

5.  Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications.

Authors:  W K Wang; T Dudek; M Essex; T H Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

6.  The human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1 DCAF1 ubiquitin ligase to overcome a postentry block in macrophage infection.

Authors:  Anna Bergamaschi; Diana Ayinde; Annie David; Erwann Le Rouzic; Marina Morel; Gilles Collin; Diane Descamps; Florence Damond; Françoise Brun-Vezinet; Sebastien Nisole; Florence Margottin-Goguet; Gianfranco Pancino; Catherine Transy
Journal:  J Virol       Date:  2009-03-04       Impact factor: 5.103

7.  DC-SIGN from African green monkeys is expressed in lymph nodes and mediates infection in trans of simian immunodeficiency virus SIVagm.

Authors:  Mickaël J-Y Ploquin; Ousmane M Diop; Nathalie Sol-Foulon; Lorenzo Mortara; Abdourahmane Faye; Marcelo A Soares; Eric Nerrienet; Roger Le Grand; Yvette Van Kooyk; Ali Amara; Olivier Schwartz; Françoise Barré-Sinoussi; Michaela C Müller-Trutwin
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

8.  Decidual soluble factors participate in the control of HIV-1 infection at the maternofetal interface.

Authors:  Romain Marlin; Marie-Thérèse Nugeyre; Marion Duriez; Claude Cannou; Anne Le Breton; Nadia Berkane; Françoise Barré-Sinoussi; Elisabeth Menu
Journal:  Retrovirology       Date:  2011-07-18       Impact factor: 4.602

9.  A human monoclonal antibody blocks malaria transmission and defines a highly conserved neutralizing epitope on gametes.

Authors:  Camila H Coelho; Wai Kwan Tang; Martin Burkhardt; Jacob D Galson; Olga Muratova; Nichole D Salinas; Thiago Luiz Alves E Silva; Karine Reiter; Nicholas J MacDonald; Vu Nguyen; Raul Herrera; Richard Shimp; David L Narum; Miranda Byrne-Steele; Wenjing Pan; Xiaohong Hou; Brittany Brown; Mary Eisenhower; Jian Han; Bethany J Jenkins; Justin Y A Doritchamou; Margery G Smelkinson; Joel Vega-Rodríguez; Johannes Trück; Justin J Taylor; Issaka Sagara; Sara A Healy; Jonathan P Renn; Niraj H Tolia; Patrick E Duffy
Journal:  Nat Commun       Date:  2021-03-19       Impact factor: 17.694

10.  Neutralization sensitivity of HIV-1 subtype B' clinical isolates from former plasma donors in China.

Authors:  Yabo OuYang; Jianping Sun; Yang Huang; Lu Lu; Weisi Xu; Xintao Hu; Kunxue Hong; Shibo Jiang; Yiming Shao; Liying Ma
Journal:  Virol J       Date:  2013-01-05       Impact factor: 4.099

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.